OUP user menu

Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level

Liselotte C. van Asten, Faroudy Boufassa, Veronique Schiffer, Raymond P. Brettle, J. Roy Robertson, Ildefonso Hernádez Aguado, Jim McMenamin, Robert Zangerle, Arnaud Fontanet, Roel A. Coutinho, Maria Prins
DOI: http://dx.doi.org/10.1093/eurpub/13.4.347 347-349 First published online: 1 December 2003


There is evidence that HIV-positive injecting drug users benefit less than other risk groups from highly active antiretroviral therapy that has been available since 1996. In this multicentre European study the impact of the availability of highly active antiretroviral therapy on the progression rates to AIDS and death among injecting drug users with a documented date of HIV seroconversion is studied. After highly active antiretroviral therapy became available the risk of AIDS and death for injecting drug users decreased by 28% and 36%, which is less than has been reported for other risk groups.

  • Europe, highly active antiretroviral therapy, HIV disease progression, IV drug users, survival analysis

Received 31 January 2002. Accepted 16 July 2002.